4,000
Participants
Start Date
January 25, 2024
Primary Completion Date
November 30, 2025
Study Completion Date
February 28, 2026
Single-gene Noninvasive Prenatal Testing (sgNIPT)
Natera sgNIPT is intended for use in pregnant people whose 'fetus/ fetuses are identified as at increased risk for a single gene disorder when there is no reproductive partner (paternal) screening available or when there is positive reproductive partner screening, but prenatal diagnostic testing is not an option or when there is concern for a single-gene disorder in the fetus/ fetuses irrespective of carrier status (e.g., based on fetal ultrasound findings).
RECRUITING
NYU Langone, New York
RECRUITING
Icahn School of Medicine at Mount Sinai, New York
RECRUITING
Weill Medical College of Cornell University, New York
RECRUITING
Northwell (Northshore/LIJ), New Hyde Park
RECRUITING
NYU Langone Hospital, Garden City
RECRUITING
University of Rochester, Rochester
RECRUITING
Orlando Health Inc. (Winnie Palmer Hsopital), Orlando
RECRUITING
UMMC WH Univerity Center For Fetal Medicine, Jackson
RECRUITING
PEDIATRIX Medical Services, Inc. Master + Houston, Stafford
RECRUITING
University of Texas Medical Branch (UTMB), Galveston
RECRUITING
Austin Maternal Fetal Medicine/St. Davids Healthcare, Austin
RECRUITING
Valley Perinatal, Glendale
RECRUITING
Cedars Sinai Prenatal Diagnosis Center, Los Angeles
RECRUITING
Center for Fetal Medicine and Womens Ultrasound, Los Angeles
RECRUITING
Natera Inc, San Carlos
RECRUITING
University of California San Francisco, San Francisco
RECRUITING
Capital Health, Lawrenceville
RECRUITING
Rutgers Robert Wood Johnson Medical School, New Brunswick
Lead Sponsor
Natera, Inc.
INDUSTRY